U.S FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs

Sept 25 (Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk…
Read the full story: Reuters: Healthcare